DelveInsight’s “Dravet Syndrome Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Dravet Syndrome pipeline landscapes. It comprises Dravet Syndrome pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Dravet Syndrome therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Dravet Syndrome pipeline products.
Some of the key takeaways of the Dravet Syndrome Pipeline Report
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Biocodex and GW Pharmaceuticals, etc., are developing therapies for the treatment of Dravet Syndrome.
Emerging therapies such as Diacomit and Epidiolex, are expected to have a significant impact on the Dravet Syndrome market in the coming years.
OV935 (TAK-935), being co-developed by Ovid Therapeutics, Takeda is a first-in-class, highly selective inhibitor of the enzyme cholesterol 24 hydroxylase. Currently, the company is conducting Phase II trials after completing four Phase I trials in healthy volunteers.
Get an overview of pipeline landscape @ Dravet Syndrome Clinical Trials Analysis
A dravet syndrome is a severe form of epilepsy characterized by frequent, prolonged seizures often triggered by high body temperature (hyperthermia), developmental delay, speech impairment, ataxia, hypotonia, sleep disturbances, and other health problems.
Dravet Syndrome Emerging Drugs
Epidiolex by GW Pharmaceuticals
And others.
Scope of Dravet Syndrome Pipeline Drug Insight
Coverage: Global
Major Players: Biocodex, GW Pharmaceuticals, and others.
Pipeline Therapies: Diacomit, Epidiolex, and others.
Table of Contents
1
Dravet Syndrome Report Introduction
2
Dravet Syndrome Executive Summary
3
Dravet Syndrome Overview
4
Dravet Syndrome- Analytical Perspective In-depth Commercial Assessment
5
Dravet Syndrome Pipeline Therapeutics
6
Dravet Syndrome Late Stage Products (Phase II/III)
7
Dravet Syndrome Mid Stage Products (Phase II)
8
Dravet Syndrome Early Stage Products (Phase I)
9
Dravet Syndrome Preclinical Stage Products
10
Dravet Syndrome Therapeutics Assessment
11
Dravet Syndrome Inactive Products
12
Company-University Collaborations (Licensing/Partnering) Analysis
13
Dravet Syndrome Key Companies
14
Dravet Syndrome Key Products
15
Dravet Syndrome Unmet Needs
16
Dravet Syndrome Market Drivers and Barriers
17
Dravet Syndrome Future Perspectives and Conclusion
18
Dravet Syndrome Analyst Views
19
Appendix
20
About DelveInsight
Related Reports:
Dravet Syndrome Market
DelveInsight’s Dravet Syndrome – Market Insights, Epidemiology, and Market Forecast-2030 report delivers an in-depth understanding of the Dravet Syndrome, historical and forecasted epidemiology as well as the Dravet Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Dravet Syndrome Epidemiology
DelveInsight’s Dravet Syndrome – Epidemiology Forecast to 2030 report delivers an in-depth understanding of the disease, historical and forecasted Dravet Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: www.delveinsight.com/